Latest News | Theragnostic Imaging

SMRD 2025

Wed, 24 Dec 2025 00:00:00 +0000

The second Symposium on Molecular Radiotherapy Dosimetry (SMRD), subtitled
“The Future of Theragnostics”, was organized by the EFOMP Special Interest Group on Radionuclide Internal Dosimetry and hosted by the Hellenic Association of Medical Physics in Athens, Greece, in mid-November 2025. Monika and Caroline contributed to the symposium with a scientific presentation and an invited presentation.

Monika and Caroline contributed to the scientific programme with an oral presentation on tumour-to-kidney absorbed dose ratios for PRRT therapies for alpha-emitting radionuclides. Caroline gave an invited presentation with updates from the EANM. In addition, a presentation of a joint EANM/EFOMP dosimetry software tender document, of which Caroline has contributed, was given during the meeting.

Slides from the invited talks, as well as the abstract book, have been published online. Direct links to abstracts involving contributions from our group can be found here and here.

KRN article of the year 2024/2025

Mon, 10 Nov 2025 00:00:00 +0000

Our group is proud to announce that we have been awarded the Division of Radiology and Nuclear Medicine (KRN) Best Article of the Year 2024/2025 for our outstanding work on the First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted ²¹²Pb Radioligand in Patients with Metastatic Castration-Resistant Prostate Cancer. The award was presented by division head Paulina Due-Tønnessen on Wednesday October 29th, followed by a presentation by senior author Caroline. This paper was a result of a fruitful collaboration between several groups at OUS, and the trial itself was sponsored by ARTBIO (PI Kjetil Berner from the Department of Oncology, OUS). Congratulations to our group members Eivor Hernes, Monika Kvassheim, Simen Rykkje Grønningsæter and Caroline Stokke, as well as the whole team on this well-deserved recognition!

Link to the paper

EANM 2025 - Barcelona

Wed, 05 Nov 2025 00:00:00 +0000

A brilliant way to spend time in sunny Spain in October is in the gentle breeze of conference air conditioning. Our group attended EANM 2025, this year held in Barcelona.

The research group at EANM 2025

This year we had four presentations from our group. These included two top-rated oral presentations, one given by Monika (Systematic Comparison of Reported PRRT Tumour Dose-Response Relationships in an Independent Cohort; Pilot Results for Tumour Absorbed Dose) and one by Sindre: “Potential for home-based blood sampling for estimating maximum tolerated activity for [131I]-NaI dosimetry-patients”. We also had two posters, one with Johan as first author (“Prognostic Value of First Order Radiomic Features in Multiple Myeloma: Data Analysis from the CONPET Trial”) and one with Helena (“Radioimmunotherapy of Non-Hodgkin Lymphoma with Lilotomab Conjugated to Different Radionuclides: A Simulation Study”).

As usual, Caroline chaired several sessions, including a top-rated oral presentation session “Quantification and Innovation in Dosimetry”, a Learn and Improve Professional Skills session on “Pitfalls in PSMA-Based RLT: Case-Based Review” organised by the Oncology & Theranostics Committee (together with Dr. Matteo Bauckneht), and a Continuing Medical Education (CME) session on “Challenges in Red Bone Marrow Dosimetry” (together with Prof. Peter Bernhardt).

Monika presenting our work on tumour dosimetry methodology comparisons. This is part of a larger project dedicated to reproduce tumour absorbed dose – response correlations for 177Lu-PRRT.

Sindre presentinged our work on home-based blood sampling for patients receiving [¹³¹I]NaI treatment.

Caroline chaired several sessions, including a top-rated oral presentation session, a “Learn and Improve Professional Skills” session, and a Continuing Medical Education session. The picture shows her together with her co-chair, Prof. Peter Bernhardt from the University of Gothenburg.

Caroline chairing the CME session together with Prof. Peter Bernhardt from the University of Gothenburg.

Our traditional group dinner on the penultimate conference day

Official opening of RNTreg OUS

Mon, 23 Jun 2025 00:00:00 +0000

The radionuclide therapy patient registry at Oslo University Hospital (RNTreg OUS) is now open! The registry was approved in March 2025, with the aim to collect retrospective data from the past ten years while continuing to include current and future patients.

The official opening took place on June 23, 2025. The registry will facilitate research and improve patient care by making data on radionuclide therapy more accessible to researchers and clinicians.

For an overview of the registry, please see the RNTreg OUS page.

Paper on the Phase 0-trial of AB001 accepted for publication

Fri, 21 Mar 2025 00:00:00 +0000

Our research group is pleased to announce that we have had results from a phase 0-trial on AB001, a novel PSMA-targeted radioligand labeled with the α-emitter 212Pb, accepted for publication in the Journal of Nuclear Medicine. The study explores the use of γ-camera imaging to assess biodistribution and uptake of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC).

The study was conducted at Oslo University Hospital, and sponsored by ARTBIO. The publication was a result of an excellent multidisiplinary collaboration, and especially the joint first authors Kjetil Berner (Department of Oncology) and Eivor Hernes (Department of Nuclear Medicine), together with Monika Kvassheim and senior author Caroline Stokke (our group) played key roles. Group members Simen Rykkje Grønningsæter and Lars Tore Gyland Mikalsen also gave valuable contributions. The work showed that AB001 can be safely administered and imaged at a microdose of only 10 MBq, and successfully demonstrated metastatic targeting. The findings offer valuable insights into the biodistribution and clearance of 212Pb-labeled radioligands, paving the way for further clinical development in targeted alpha therapy.

Link to the (Open Acces) publication ahead of print

Position Open for a Medical Physicist at Oslo University Hospital

Sat, 25 Jan 2025 00:00:00 +0000

The Section for Nuclear Medicine Physics at Oslo University Hospital (OUS) is offering a full-time temporary position for a medical physicist. The role involves a mix of clinical tasks and professional development in the field of diagnostic and therapeutic nuclear medicine, with a focus on precision medicine. You will work as part of an engaged and collaborative team, contributing to both daily operations and ongoing research activities.

Our department is equipped with advanced facilities, including PET/CT and SPECT/CT scanners, and collaborates closely with national and international partners. The position offers opportunities for tailored training and certification, and there is potential for extension based on project needs. This role suits individuals with a structured and proactive approach who are motivated by interdisciplinary work and professional growth.

For more information about the position and how to apply, see this link

Research Grant Awarded to Advance Alpha Therapy Imaging

Sun, 22 Dec 2024 00:00:00 +0000

The Theragnostic Imaging group has received funding for a three-year full time research position + running costs from the Southern and Eastern Norway Regional Health Authority for ImALPHA! The research project is aiming to advance post-treatment imaging of targeted alpha therapy.

Alpha therapy imaging with current technology suffers from low count rates and high scatter. Building on our previous pilot studies and early-phase clinical trials, the project will develop new imaging technologies specifically adapted to these challenges. The research will include the development of optimized reconstruction built with refined simulation models for camera response, validation through prospective studies with parallel clinical trials, and in silico models to prepare future clinical trials.

Caroline Stokke is PI and group member Monika Kvassheim will be closely involved.

Presentation at 6th Targeted Radiopharmaceutical Summit Europe

Thu, 05 Dec 2024 00:00:00 +0000

Caroline Stokke delivered an invited plenary presentation on “Dosimetry for first-in-human studies and early phase clinical trials” at the 6th Targeted Radiopharmaceutical Summit Europe. Dosimetry is an essential aspect of clinical radiopharmaceutical development, and Caroline outlined the procedures in the EANM guidance document () in a well-received presentation. Group members Monika Kvassheim and Caroline Stokke both participated in the event, which is an established forum for the radiopharmaceutical community. The summit took place in beautiful Amsterdam and provided valuable opportunities for knowledge exchange with other researchers and industry professionals in the radiopharmaceuticals field.

EANM 2024 - Hamburg

Fri, 04 Oct 2024 00:00:00 +0000

Our group attended EANM 2024, which was held in Hamburg, Germany. We had a great experience presenting our own work and getting inspired by the fascinating research being done in the field of nuclear medicine. Our group made a sizeable contribution to the conferences academic program, with three e-posters, four top rated oral presentations and multiple sessions chaired by Caroline.

Mia presented results from her master thesis, conducted in our group and titled " Comparing the Impact of Dosimetry at Different Scales for Alpha and Beta Emitters in Molecular Radiotherapy Using Monte Carlo Simulations".

Monika presented work from our group titled “The Impact of Assumptions on Kidney Absorbed Doses When Modelling Redistribution of Daughters for Alpha- Emitter Based Somatostatin Receptor Therapies”.

As has become tradition by now, the group ate dinner together on the conference penultimate day, this year there were some special guest appearances(!)

Full list of contributions, abstracts can be read in the abstract book of the conference found here

Impact of Total Tumour Absorbed Dose and Total Metabolic Tumour Volume on Progression Free Survival in the Phase 1/2a Study of [177Lu]Lu-Lilotomab Satetraxetan for Treatment of Relapsed Indolent Non-Hodgkin Lymphoma
The Impact of Assumptions on Kidney Absorbed Doses When Modelling Redistribution of Daughters for Alpha- Emitter Based Somatostatin Receptor Therapies
Comparing the Impact of Dosimetry at Different Scales for Alpha and Beta Emitters in Molecular Radiotherapy Using Monte Carlo Simulations
Quantification Accuracy of SPECT Imaging with Low 212Pb Activity Concentrations; Assessments by 3D-Printed Anthropomorphic Phantoms
[18F] Fluciclovine Compared to [18F]FDG for Multiple Myeloma Imaging
Estimating lung lesion mass for dosimetry purposes using an oversized VOI in CT images
Dose rate measurements when working with Gallium 68

Congratulations Mia and Johan!

Thu, 20 Jun 2024 00:00:00 +0000

Mia Frivik and Johan Høiness have defended their master’s theses. Johan was supervised by Monika Kvassheim, Caroline Stokke, and Eivor Hernes, while Mia was supervised by Monika Kvassheim, Caroline Stokke, and Andreas Tulipan.

Caroline becomes chair of the EANM Dosimetry Commitee

Sat, 10 Feb 2024 00:00:00 +0000

Caroline Stokke has been appointed Chair of the Dosimetry Committee within the European Association of Nuclear Medicine (EANM) after serving as a committee member for five years. In her role as Chair, she works to promote dosimetry practices, develop guidelines, and support education and training initiatives, all aimed at optimizing the use of radiopharmaceuticals in nuclear medicine. Her first term spans three years (2024–2026), with the possibility of a second three-year term.

The year of 2023 for "Theragnostic Imaging"

Mon, 01 Jan 2024 00:00:00 +0000

The year 2023 has been an active and productive one for our research group, reflecting the collective efforts of our members and collaborators. We are pleased to report 17 publications in peer-reviewed journals, covering topics ranging from dosimetry in molecular radiotherapy to imaging optimization and clinical applications. These publications reflect the broad scope of our work and our commitment to advancing nuclear medicine physics.

Our team also had a strong presence at international conferences, delivering 14 presentations at international meetings such as EANM 2023, SNMMI 2023, and BiGART 2023. These included both invited talks and research presentations, addressing topics like theragnostic dosimetry, radiomic analysis, and clinical trial results. Members of our group also contributed to conference organization, serving on abstract committees and chairing multiple sessions.

This year also brought opportunities for mentorship and recognition. We supported early-career researchers through involvement in PhD defenses and master’s thesis evaluations. Notably, our group received the Clinical Paper of the Year award from Molecular Imaging and Biology, acknowledging our contributions to advancing imaging and treatment strategies in non-Hodgkin lymphoma. As the year ends, we look forward to continuing our collaborative efforts to improve diagnostic and therapeutic approaches in nuclear medicine.

Caroline joins the executive board of EURAMED

Tue, 10 Oct 2023 00:00:00 +0000

Caroline has joined the Board of Executives of EURAMED, the European Alliance for Medical Radiation Protection Research. She will serve as the EANM representative on the board. In this capacity, she contributes to efforts to improve medical care through sustainable research in radiation protection, foster collaboration among researchers and clinicians, and support harmonized strategies for advancing European research initiatives in radiation protection.

Caroline has joined the Board of Executives of EURAMED, the European Alliance for Medical Radiation Protection Research. She will serve as the EANM representative on the board. In this role, she contributes to efforts aimed at improving medical care through sustainable research in radiation protection, fostering collaboration among researchers and clinicians, and supporting harmonized strategies for advancing European research initiatives in radiation protection.

Link to the EURAMED announcement

EANM 2023 Vienna

Wed, 04 Oct 2023 00:00:00 +0000

Our group attended EANM 2023 in Vienna, Austria. We had a wonderful time presenting our work and engaging with the nuclear medicine community.

Our group made a total of eleven contribution, of which ten were with a group member as first author. Caroline chaired and or coordinated and chaired a joint session with ESTRO, a CME on radiobiology and a TROP session on clinical dosimetry.

Ayca et. al. receives Clinical paper of the Year!

Thu, 21 Sep 2023 00:00:00 +0000

Ayca Løndalen received the prize for Clinical Paper of the Year for her work published in “FDG PET/CT and Dosimetric Studies of [177Lu]Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent Non-Hodgkin Lymphoma—Are We Hitting the Target?” in Molecular Imaging and Biology. The award was presented at the World Molecular Imaging Congress in Prague.

Congratulations Ebba!

Fri, 25 Aug 2023 00:00:00 +0000

On Thursday, 25.08.2023, Ebba Gløersen Muller defended her PhD thesis titled “[18F]Flutemetamol PET/CT for the Diagnosis of Alzheimer’s Disease – Clinical Value and Reference Levels.” We congratulate Ebba, as well as the supervisory team: Mona-Elisabeth Revheim (main supervisor), Anne Brita Knapskog, and Caroline Stokke.

Congratulations Ayca!

Thu, 02 Feb 2023 00:00:00 +0000

On Thursday, 02.02.2023, our research group member Ayca Løndalen (MD) defended her PhD thesis titled “FDG PET/CT and Dosimetry Studies After Targeted Therapy with [177Lu]Lu-Lilotomab Satetraxetan.” She was supervised by Caroline Stokke (main supervisor), Mona-Elisabeth Revheim, and Arne Kolstad.

The year of 2022 for "Theragnostic Imaging"

Sun, 01 Jan 2023 00:00:00 +0000

In 2022, the group focused on advancing the understanding of radionuclide therapies and improving dosimetry methods. A total of eight publications were produced, including both original research and a review paper on radionuclides for targeted therapy. Notable studies included dosimetric studies of 177Lu-lilotomab satetraxetan in non-Hodgkin lymphoma and contributions to the EANM dosimetry committee’s recommendations for 177Lu-labelled ligands.

Presentations were delivered at key international and national conferences. Highlights include invited talks at the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI), covering topics such as first-in-human dosimetry, the biodistribution of radium-224, and imaging advancements with Lead-212. Several national talks also focused on dosimetry for alpha-particles and PRRT.

The year also involved continued mentoring of graduate students, with one doctoral student and one master’s student successfully completing their theses under the group’s supervision. The group participated in abstract committees for both the EANM 2023 and NACP 2023 conferences, as well as chaired sessions at EANM 2022.

Overall, 2022 was a year of productive research dissemination and mentorship, with significant contributions to both the scientific community and education.

Caroline Stokke to lead work package on Theranostic radiopharmaceuticals for metastatic cancer

Fri, 23 Dec 2022 00:00:00 +0000

Caroline will lead a work package focusing on targeted alpha therapy, funded by a grant from the South-Eastern Norway Regional Health Authority. We will recruit a PhD student for this project.

Vice chair of the EANM Dosimetry Commitee

Mon, 10 Oct 2022 00:00:00 +0000

Our group leader of Theragnostic Imaging has been appointed vice chair of the Dosimetry Committee within the European Association of Nuclear Medicine (EANM). In this role, she contributes to advancing the field of dosimetry.

Caroline to co-lead work package in the SIMPLERAD consortium

Wed, 01 Jun 2022 00:00:00 +0000

SIMPLERAD is a two-year project led by a consortium of three European medical societies—EIBIR, EANM, and EFOMP—bringing together expertise in nuclear medicine, medical physics, radiopharmacy, and regulatory science to address key challenges in medical radiation. The project’s progress is structured into four work packages. Caroline Stokke has been appointed to co-lead Work Package 4, focusing on organizing a workshop to present and validate findings from previous work packages and foster dialogue on the regulation, development, and use of therapeutic nuclear medicine. This initiative will bring together a diverse group of stakeholders, including regulatory authorities, researchers, clinicians, patient organizations, and industry representatives.

Congratulations Johan!

Fri, 18 Feb 2022 00:00:00 +0000

On 18.02.2022, Johan Blakkisrud defended his PhD thesis titled “Dosimetry in Patients Treated with [177Lu]Lu-lilotomab Satetraxetan.” He was supervised by Caroline Stokke (main supervisor), Anne Catrine Martinsen, and Arne Kolstad. The work was funded by a grant from the South-Eastern Norway Regional Health Authority.